Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv


Oslo, October 25, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the results from Phase II FOCUS trial (NCT05075122) have been published online on the preprint platform medRxiv.

Read the original:
Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv

Related Posts